

Jan Oscarsson

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4585055/jan-oscarsson-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11
papers

385
citations

7
h-index

14
g-index

14
ext. papers

588
ext. citations

7.4
avg, IF

3.55
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 11 | Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. <i>Diabetologia</i> , 2018 , 61, 1923-1934 | 10.3 | 160 |
| 10 | The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients. <i>Diabetes Care</i> , 2019 , 42, 931-937 | 14.6 | 81 |
| 9 | MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?. <i>European Journal of Endocrinology</i> , 2018 , 178, R113-R125 | 6.5 | 51 |
| 8 | Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 586-594 | 18.1 | 38 |
| 7 | Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 886-896 | 6.7 | 19 |
| 6 | Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1505-1517 | 6.7 | 11 |
| 5 | Importance of pancreatic exocrine dysfunction in patients with type 2 diabetes: A randomized crossover study. <i>Pancreatology</i> , 2018 , 18, 550-558 | 3.8 | 10 |
| 4 | Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients-a description of the DAPACARD study. <i>Upsala Journal of Medical Sciences</i> , 2019 , 124, 59-64 | 2.8 | 7 |
| 3 | Association of faecal elastase 1 with non-fasting triglycerides in type 2 diabetes. <i>Pancreatology</i> , 2016 , 16, 563-9 | 3.8 | 3 |
| 2 | Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?. <i>Molecular Metabolism</i> , 2021 , 46, 101158 | 8.8 | 3 |
| 1 | Dapagliflozin in patients with COVID-19: mind the kidneys - AuthorsYreply.. <i>Lancet Diabetes and Endocrinology</i> , 2021 , | 18.1 | |